A brand new research printed in Nature Drugs on Monday reveals that weight-loss medicine like Ozempic and Mounjaro do extra than simply shrink waistlines—they could additionally scale back the chance of sure illnesses, together with Alzheimer’s, coronary heart illness, and liver most cancers. Nonetheless, the research discovered these drugs can include dangers, together with gastrointestinal points, arthritis, kidney issues, and pancreatitis.
The research, “Mapping the Effectiveness and Dangers of GLP-1 Receptor Agonists,” was performed by researchers from the U.S. Division of Veterans Affairs in St. Louis and Ewha Womans College in Seoul, South Korea. It discovered that folks taking GLP-1 agonists had a diminished danger for 42 situations, together with a 9% decrease danger of coronary heart assaults and an 8% decrease danger of dementia.
“What this paper reveals is that treating weight problems and metabolic syndrome seemingly has a broad well being profile,” mentioned Dr. Ziyad Al-Aly, chief of analysis and improvement on the VA St. Louis Well being Care System.
Launched in December 2017 by drug producer Novo Nordisk, Ozempic is a prescription injectable medicine for treating type-2 diabetes in adults. It gained reputation when Novo Nordisk scientists found that the drug simulates naturally produced hormones that curb urge for food and gradual digestion, resulting in weight reduction in some customers.
“These medicine additionally scale back irritation within the mind and lead to weight reduction,” Al-Aly mentioned. “Each these components could enhance mind well being and clarify the diminished danger of situations like Alzheimer’s illness and dementia.”
Weight problems stays a major well being problem within the U.S.; a Might 2024 report by the Facilities for Illness Management states that two in 5 adults—roughly 41.9%, round 100 million individuals—of U.S. adults reside with weight problems.
“We all know weight problems is dangerous for a lot of, many issues, and now we now have empiric proof that treating weight problems produces good well being advantages throughout the board past simply discount in weight,” Al-Aly mentioned. “However there are additionally dangers, and we hope these findings immediate dialogue with individuals and their suppliers.”
By analyzing almost 2 million medical data from the U.S. Division of Veterans Affairs, researchers in contrast people taking GLP-1 receptor agonists with these utilizing different diabetes remedies or older drugs.
Consciousness of GLP-1RAs is rising, resulting in new alternatives for combating weight problems as their use turns into extra widespread.
Final yr, in a 2024 KFF Well being Monitoring Ballot, 12% of adults reported taking these drugs. Utilization is especially excessive amongst people with diabetes (45%), coronary heart illness (41%), or weight problems (42%). However whereas 40% of customers flip to those medicine primarily for weight reduction, value stays a barrier for 54% of these surveyed.
Edited by Andrew Hayward
Usually Clever Publication
A weekly AI journey narrated by Gen, a generative AI mannequin.
